Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Canasa (Mesalamine) Suppository for Treatment of Ulcerative Proctitis Launched in US MONT SAINT-HILAIRE, QC -- February 28, 2005 -- Axcan Pharma Inc. ("Axcan" or the "Company") announced today the launch of Canasa 1000 mg, the only FDA approved once-daily mesalamine suppository for the treatment of ulcerative proctitis. Axcan received a three-year marketing exclusivity for the new dosage form under the non-patent exclusivity provisions of the Federal Food, Drug and Cosmetic Act. "The once-a-day Canasa 1000 mg suppository offers a new treatment option for patients with ulcerative proctitis," said Dr. Miguel Regueiro, Associate Professor of Medicine and Co-Director of the Inflammatory Bowel Disease Center at the University of Pittsburgh Medical Center. "The 1000 mg suppository is as efficacious as the twice-a-day Canasa 500 mg suppository, but 1000 milligrams once a day is easier for patients to use and should improve compliance." In the United States, the rectal mesalamine market is valued at approximately U.S. $82 million annually. According to IMS Health data published in December 2004, approximately 56% of all U.S. gastrointestinal prescriptions for rectal mesalamine were written for Canasa 500 mg, making Axcan's Canasa 500 mg the most prescribed brand of rectal mesalamine in the U.S. About Ulcerative Proctitis Ulcerative proctitis is a subgroup of ulcerative colitis, one of the most common inflammatory bowel diseases. In approximately 30% of patients with ulcerative colitis, the illness begins as ulcerative proctitis where bowel inflammation is limited to the rectum. Currently, it is estimated that there are approximately 1,000,000 cases of inflammatory bowel disease in the U.S. with approximately 400,000 new cases every year. The name Canasa is a trademark of Axcan Pharma Inc. and its subsidiaries. SOURCE: Axcan Pharma Inc E-mail this page to a friend or colleague! To print, use this version